Rankings
▼
Calendar
ESPR FY 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ESPR
Esperion Therapeutics, Inc.
$577M
FY 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$332M
+185.7% YoY
Gross Profit
$264M
79.4% margin
Operating Income
$54M
16.4% margin
Net Income
-$52M
-15.6% margin
EPS (Diluted)
$-0.28
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$24M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$344M
Total Liabilities
$733M
Stockholders' Equity
-$389M
Cash & Equivalents
$145M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$332M
$116M
+185.7%
Gross Profit
$264M
$73M
+260.9%
Operating Income
$54M
-$156M
+135.0%
Net Income
-$52M
-$209M
+75.3%
← Q4 2023
All Quarters
Q1 2024 →